Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The Beta-blocker Heart Attack Trial.

C D Furberg

    Zeitschrift Fur Kardiologie
    |January 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Long-term beta-blocker therapy, specifically propranolol, significantly reduces mortality after myocardial infarction. This treatment is most beneficial for high-risk patients within the first 12-18 months post-heart attack.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Lipoprotein-associated phospholipase A2 (Lp-PLA2) and future risk of type 2 diabetes: results from the Cardiovascular Health Study.

    The Journal of clinical endocrinology and metabolism·2012
    Same author

    Double-blindness protects scientific validity.

    Journal of thrombosis and haemostasis : JTH·2007
    Same author

    Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel.

    Journal of internal medicine·2006
    Same author

    Drug safety: the different perspectives.

    Evidence-based cardiovascular medicine·2005
    Same author

    Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment.

    Lancet (London, England)·2003
    Same author

    Doxazosin, an inferior antihypertensive agent?

    Journal of human hypertension·2002
    Same journal

    [Not Available].

    Zeitschrift fur Kardiologie·2016
    Same journal

    [Not Available].

    Zeitschrift fur Kardiologie·2016
    Same journal

    [On pathogenesis of coronary heart disease].

    Zeitschrift fur Kardiologie·2016
    Same journal

    An overview of the evolution of the atherosclerotic plaque: from fatty streak to plaque rupture and thrombosis.

    Zeitschrift fur Kardiologie·2016
    Same journal

    [Not Available].

    Zeitschrift fur Kardiologie·2016
    Same journal

    [Reconstructive surgery of the aortic root].

    Zeitschrift fur Kardiologie·2016
    See all related articles

    Area of Science:

    • Cardiology
    • Pharmacology
    • Clinical Trials

    Background:

    • Myocardial infarction survivors require long-term management to prevent mortality.
    • Beta-blocker therapy is a potential strategy for secondary prevention post-myocardial infarction.

    Purpose of the Study:

    • To evaluate the long-term preventive effects of beta-blocker therapy in myocardial infarction survivors.
    • To identify patient subgroups that benefit most from this intervention.

    Main Methods:

    • Analysis of controlled clinical trials, including the large-scale Beta-Blocker Heart Attack Trial.
    • Assessment of propranolol dosage (180-240 mg daily) in patients without contraindications.

    Main Results:

    • Propranolol therapy demonstrated a significant mortality benefit in myocardial infarction survivors.

    Related Experiment Videos

  • Benefits were most pronounced in the initial 12-18 months post-infarction.
  • High-risk patients, including those with complicated infarctions or arrhythmias, showed the greatest benefit.

    • Conclusions:

    • Long-term beta-blocker therapy, particularly propranolol, is effective in prolonging life after myocardial infarction.
    • The anti-arrhythmic and anti-ischemic mechanisms are likely key to its efficacy.
    • Targeting high-risk patients optimizes the benefits of beta-blocker treatment.